LTT Biopharma Interstitial Pneumonia Drug Obtains MHLW Orphan Status
This article was originally published in PharmAsia News
The First Committee on New Drugs at the Ministry of Health, Labor and Welfare June 4 granted orphan drug status to LTT Biopharma's midismase (recombinant) for interstitial pneumonia. Midismase is a lecithinized superoxide dismutase (PC-SOD) that is in Phase II clinical trials in Japan. Tokyo-based LTT specializes in developing new drug delivery systems, and the orphan status will accelerate the regulatory approval process and help obtain financial assistance. (Click here for more - Japanese language)"LTT Biopharma Shares Jump Due To Obtaining Orphan Drug Status For New Drug" - Search China News (6/7/2010)
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.